BlossomHill Therapeutics (NASDAQ:BLSM) Issues Earnings Results, Misses Estimates By $7.91 EPS

Posted by Brian Himes on Sep 18th, 2026

BlossomHill Therapeutics (NASDAQ:BLSM – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91), Zacks reports.

BlossomHill Therapeutics Trading Up 2.2%

Shares of NASDAQ BLSM opened at $26.82 on Friday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $27.80.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Leerink Partners started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “outperform” rating and a $36.00 price objective on the stock. Guggenheim began coverage on shares of BlossomHill Therapeutics in a research report on Tuesday, September 1st. They set a “buy” rating and a $30.00 price objective for the company. Zacks Research raised shares of BlossomHill Therapeutics to a “hold” rating in a research report on Wednesday, September 2nd. HC Wainwright started coverage on shares of BlossomHill Therapeutics in a report on Tuesday, September 1st. They set a “buy” rating and a $35.00 target price for the company. Finally, Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set an “outperform” rating and a $32.00 target price on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, BlossomHill Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $32.20.

Check Out Our Latest Stock Analysis on BlossomHill Therapeutics

Insider Buying and Selling at BlossomHill Therapeutics

In other news, Director Bihua Chen acquired 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the purchase, the director directly owned 3,614,034 shares of the company’s stock, valued at approximately $57,824,544. This represents a 9.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Orbimed Advisors Llc bought 625,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at approximately $43,428,464. This trade represents a 29.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 1,573,900 shares of company stock valued at $25,181,900 over the last three months.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.